After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit ...

Vertex Pharmaceuticals has hit a snag in its efforts to follow up non-opioid pain reliever Journavx (suzetrigine). | Vertex ...

Vertex Pharmaceuticals said on Monday it will not continue development of its experimental non-opioid painkiller as a solo ...

Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to provide post-surgery benefits and US regulators ...

Vertex Pharmaceuticals beat Wall Street estimates for quarterly results on Monday, helped by demand for its new cystic ...

Vertex stock falls after pain drug VX-993 fails Phase 2 trial, despite better-than-expected Q2 earnings and strong cystic ...

Shares of Vertex Pharmaceuticals sank 15% after the drugmaker announced a study showed its experimental pain medicine was not ...

Vertex Pharmaceuticals ( NASDAQ: VRTX) shares fell in premarket trading on Tuesday after the company's VX-993 failed to meet ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The Gates Foundation committed $2.5 billion through 2030 to support dozens of different approaches for improving women’s ...

Vertex stock crashed late Monday after the company said it wouldn't advance a next-generation pain drug into more testing.

As understanding grows of the scale of health care’s environmental impacts, so too does interest in measuring and reporting on sustainability as a facet of health care system performance. This ...